Circuit Therapeutics

Circuit Therapeutics. It is a biotechnology company founded in 2012 that specializes in developing novel therapies by targeting specific neural circuits in the brain. The company leverages pioneering optogenetics technology to map and modulate brain activity with high precision. Its research aims to translate discoveries in neuroscience into treatments for neurological and psychiatric disorders.

Overview

The company was established to commercialize groundbreaking research from Stanford University and the Massachusetts Institute of Technology. Its foundational work is built upon the revolutionary optogenetics techniques developed in the labs of Karl Deisseroth and Edward Boyden. The firm's mission focuses on identifying dysfunctional neural pathways underlying conditions like chronic pain, addiction, and movement disorders. It operates at the intersection of bioengineering, systems neuroscience, and pharmaceutical development.

Technology and Platforms

The core technological platform is based on optogenetics, a method that uses light to control neurons genetically modified to express light-sensitive opsin proteins. This allows for unprecedented precision in activating or inhibiting specific neural circuits. The company also utilizes advanced viral vector delivery systems, such as those derived from adeno-associated virus, to target gene therapies to particular brain regions. Complementary platforms include chemogenetics and advanced imaging techniques for circuit mapping. These tools enable the development of potential gene therapies designed to rewire faulty neural networks.

Research and Applications

Primary research areas include chronic neuropathic pain, where the company investigates circuits in the periaqueductal gray and the anterior cingulate cortex. Another major focus is on substance use disorders, targeting reward pathways involving the nucleus accumbens and the ventral tegmental area. The company is also exploring applications in Parkinson's disease and other movement disorders by modulating circuits in the basal ganglia. Early-stage research extends to psychiatric conditions such as depression and anxiety disorders.

Collaborations and Partnerships

The company has engaged in significant strategic alliances to advance its programs. A major multi-year collaboration was formed with Genentech, a member of the Roche Group, to discover and develop novel treatments for certain neurological disorders. It has also worked closely with the Michael J. Fox Foundation for Parkinson's Research on target discovery. Research partnerships continue with academic institutions like Stanford University and the Salk Institute for Biological Studies. These collaborations provide access to additional expertise in drug development and clinical trial design.

History and Founders

The company was incorporated in 2012 by a team of renowned scientists and engineers: Karl Deisseroth, a Howard Hughes Medical Institute investigator and professor at Stanford University; Edward Boyden, a professor at the Massachusetts Institute of Technology; Scott Delp, a professor of bioengineering at Stanford University; and Fritz B. Prinz, a professor in the Stanford University School of Engineering. Early funding was secured from venture capital firms including The Column Group and Lux Capital. In 2016, Frederick T. Muench, formerly of the National Institute on Drug Abuse, joined as President and CEO to guide the company's therapeutic development.

Category:Biotechnology companies of the United States Category:Companies based in San Mateo County, California Category:Neuroscience organizations